These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1551 related articles for article (PubMed ID: 12788877)
1. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877 [TBL] [Abstract][Full Text] [Related]
2. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471 [TBL] [Abstract][Full Text] [Related]
3. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881 [TBL] [Abstract][Full Text] [Related]
4. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957 [TBL] [Abstract][Full Text] [Related]
5. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Lee A; Patrick P; Wishart J; Horowitz M; Morley JE Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996 [TBL] [Abstract][Full Text] [Related]
6. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction. Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506 [TBL] [Abstract][Full Text] [Related]
7. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Vilsbøll T; Krarup T; Madsbad S; Holst JJ Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099 [TBL] [Abstract][Full Text] [Related]
8. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Vilsbøll T; Krarup T; Madsbad S; Holst JJ Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441 [TBL] [Abstract][Full Text] [Related]
9. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824 [TBL] [Abstract][Full Text] [Related]
10. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228 [TBL] [Abstract][Full Text] [Related]
11. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793 [TBL] [Abstract][Full Text] [Related]
12. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524 [TBL] [Abstract][Full Text] [Related]
13. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383 [TBL] [Abstract][Full Text] [Related]
14. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578 [TBL] [Abstract][Full Text] [Related]
15. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Frid AH; Nilsson M; Holst JJ; Björck IM Am J Clin Nutr; 2005 Jul; 82(1):69-75. PubMed ID: 16002802 [TBL] [Abstract][Full Text] [Related]
16. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Christensen MB Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187 [TBL] [Abstract][Full Text] [Related]
17. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768 [TBL] [Abstract][Full Text] [Related]
18. Gastric inhibitory polypeptide in obesity and diabetes mellitus. Service FJ; Rizza RA; Westland RE; Hall LD; Gerich JE; Go VL J Clin Endocrinol Metab; 1984 Jun; 58(6):1133-40. PubMed ID: 6373812 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Thomsen C; Storm H; Holst JJ; Hermansen K Am J Clin Nutr; 2003 Mar; 77(3):605-11. PubMed ID: 12600850 [TBL] [Abstract][Full Text] [Related]
20. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Kielgast U; Holst JJ; Madsbad S Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]